ArticleBMC nephrology2026
RNA-binding protein RBM47 promotes endothelial-to-mesenchymal transition and neointimal hyperplasia in arteriovenous fistulas.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundArteriovenous fistula (AVF) is the preferred vascular access for hemodialysis in patients with end-stage renal disease. However, AVF stenosis, a severe complication, significantly impairs the patient's quality of life. The mechanisms underlying AVF stenosis are multifactorial, with neointima (NI) hyperplasia within the fistula being a key contributor. While the involvement of RNA-binding proteins in the pathogenesis of various vascular diseases has garnered increasing attention, their role in autogenous AVFs remains poorly understood.
methodsDifferentially expressed genes in a mouse AVF model were identified through public database analysis, and quantitative real-time polymerase chain reaction (qRT-PCR) confirmed RBM47 as the most significantly altered gene. Endothelial-specific RBM47 overexpression was achieved by local delivery of adeno-associated virus (AAV)-RBM47 using F127 hydrogel. Hematoxylin-eosin staining was used to assess neointimal thickness in human and mouse AVF tissues. RBM47 expression and function were evaluated by qRT-PCR, Western blotting, and assays of proliferation and migration. Mechanistic studies, including transcriptome sequencing, Replicate Multivariate Analysis of Transcript Splicing (rMATS) analysis, RNA-Binding Protein Immunoprecipitation (RIP) Assay, molecular docking, immunohistochemistry, and immunofluorescence, were performed to investigate the relationship between RBM47, SEC31A splicing, and downstream signaling.
resultsRBM47 expression was markedly increased in stenotic AVF tissues from both patients and mouse models. Endothelial overexpression of RBM47 significantly aggravated neointimal hyperplasia. In vitro, RBM47 promoted human umbilical vein endothelial cell (HUVEC) proliferation, migration, and EndMT. Mechanistically, RBM47 was predominantly localized in the nucleus, suggesting a role in alternative splicing. Transcriptome sequencing revealed that RBM47 promoted retention of exon 13 in SEC31A, thereby suppressing the generation of the SEC31A-Δ13 splice variant. This splice variant inhibited SMAD3 phosphorylation and its downstream signaling cascade.
conclusionsRBM47 promotes neointimal hyperplasia in autogenous AVF by inducing EndMT. Specifically, RBM47 regulates alternative splicing of SEC31A and reduces the production of the SEC31A-Δ13 splice variant, which inhibits SMAD3 phosphorylation. These findings reveal a novel mechanism by which RNA-binding proteins contribute to AVF stenosis and suggest RBM47 as a potential therapeutic target for preventing AVF failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.